BMS 453A synthetic retinoid and RARβ antagonist which also displays antagonist acitivity in RARα

BMS 453 (CAS 166977-43-1)

BMS 453 | CAS 166977-43-1 is rated 5.0 out of 5 by 1.
  • y_2019, m_9, d_15, h_22
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.13
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_311294, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 93ms
  • REVIEWS, PRODUCT
Synonym: 4-[(1E)-2-(5,6-Dihydro-5,5-dimethyl -8-phenyl-2-naphthalenyl)ethenyl]-benzoic acid
Application: A synthetic retinoid and RARβ antagonist which also displays antagonist acitivity in RARα
CAS Number: 166977-43-1
Purity: ≥98%
Molecular Weight: 380.48
Molecular Formula: C27H24O2
* Refer to Certificate of Analysis for lot specific data (including water content).
Submit a review for this product and receive 15 CruzCredits

BMS 453 is a synthetic retnoid shown to be a RAR (retinoic acid receptor) antagonist. Studies note that this compound results in a block in the cell cycle at G1, causing an increase in ratio of cells in G0/G1. Further experiments suggest that BMS 453 induces Rb hypophosphorylation and lowers CDK2 kinase activity. BMS 453 also displays the capability to cause a conversion of latent transforming growth factor β (TGFβ) to active TGFβ. BMS 453 is an inhibitor of RAR α and RAR γ in vitro and an activator of RAR β in vivo.


References

1. Chen, J.Y., et al. 1995. EMBO J. 14: 1187-1197. PMID: 7720709
2. Yang, L., et al. 2001. Oncogene. 20: 8025-8035. PMID: 11753686
3. Yang, L., et al. 2001. Oncogene. 20: 8025-8035. PMID: 11753686

Physical State :
Solid
Solubility :
Soluble in DMSO (100 mM).
Storage :
Store at -20° C
Boiling Point :
560.9° C at 760 mmHg (Predicted)
Density :
1.2 g/cm3 (Predicted)
Refractive Index :
n20D 1.66 (Predicted)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
PubChem CID :
9875424
SMILES :
C1(=CC=CC=C1)C2=CCC(C3=CC=C(C=C23)C=CC4=CC=C(C=C4)C(=O)O[H])(C)C

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

BMS 453  Product Citations

See how others have used BMS 453. Click on the entry to view the PubMed entry .

Citations 1 to 1 of 1 total

PMID: # 28065603  Shrestha, S. et al. 2017. Immunol. Lett. 182: 24-29.

Citations 1 to 1 of 1 total
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 65ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from Yang Yang, L. et al. (PubMed 11753686) found that the retinoic acid receptor antagonist, BMS 453, inhibits normal breast cell growth by inducing active TGFbeta and causing cell cycle arrest. -SCBT Publication Review
Date published: 2015-04-11
  • y_2019, m_9, d_15, h_22
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.13
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_311294, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 73ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.